ICPT - Intercept Pharmaceuticals Inc Stock Price, Fair Value and News

19.00USD Market Closed

Market Summary

USD19.00

Market Closed

ICPT Stock Price

View Fullscreen

ICPT RSI Chart

ICPT Valuation

Market Cap

794.7M

Price/Earnings (Trailing)

-12.9

Price/Sales (Trailing)

2.5

Price/Free Cashflow

-12.5

ICPT Price/Sales (Trailing)

ICPT Profitability

Operating Margin

99.80%

Return on Equity

-85.76%

Return on Assets

-15.67%

Free Cashflow Yield

-8%

ICPT Fundamentals

ICPT Revenue

Revenue (TTM)

317.7M

ICPT Earnings

Earnings (TTM)

-61.6M

Breaking Down ICPT Revenue

Last 7 days

0.1%

Last 30 days

2.2%

Last 90 days

81.3%

Trailing 12 Months

27.8%

How does ICPT drawdown profile look like?

ICPT Financial Health

Current Ratio

4.22

Debt/Equity

3.12

Debt/Cashflow

-0.28

ICPT Investor Care

Shares Dilution (1Y)

33.79%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	294.5M	306.5M	317.7M	0
2022	262.6M	266.2M	277.1M	285.7M
2021	297.3M	288.3M	275.4M	260.8M
2020	272.4M	283.4M	300.9M	312.7M
2019	196.1M	218.8M	233.8M	252.0M
2018	145.9M	158.6M	164.2M	179.8M
2017	45.6M	70.9M	107.1M	131.0M
2016	1.8M	6.9M	11.6M	25.0M
2015	2.8M	2.8M	2.8M	2.8M
2014	1.6M	1.7M	1.7M	1.7M
2013	2.1M	1.7M	1.6M	1.6M
2012	2.6M	2.9M	2.8M	2.4M
2011	0	0	0	1.8M

Get all data in R, Python etc through our Historical Stock Data APIs

About Intercept Pharmaceuticals Inc

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey.

CEO	Mr. Jerome B. Durso
WEBSITE	interceptpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	341

Intercept Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Intercept Pharmaceuticals Inc? What does ICPT stand for in stocks?

ICPT is the stock ticker symbol of Intercept Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Intercept Pharmaceuticals Inc (ICPT)?

As of Tue Nov 14 2023, market cap of Intercept Pharmaceuticals Inc is 794.69 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ICPT stock?

You can check ICPT's fair value in chart for subscribers.

Is Intercept Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ICPT is over valued or under valued. Whether Intercept Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Intercept Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ICPT.

What is Intercept Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Nov 14 2023, ICPT's PE ratio (Price to Earnings) is -12.9 and Price to Sales (PS) ratio is 2.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ICPT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Intercept Pharmaceuticals Inc's stock?

In the past 10 years, Intercept Pharmaceuticals Inc has provided -0.09 (multiply by 100 for percentage) rate of return.